TY - JOUR
T1 - EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
AU - European Association for the Study of the Liver
AU - Alvaro, Domenico
AU - Gores, Gregory J.
AU - Walicki, Joël
AU - Hassan, Cesare
AU - Sapisochin, Gonzalo
AU - Komuta, Mina
AU - Forner, Alejandro
AU - Valle, Juan W.
AU - Laghi, Andrea
AU - Ilyas, Sumera I.
AU - Park, Joong Won
AU - Kelley, Robin K.
AU - Reig, Maria
AU - Sangro, Bruno
N1 - Publisher Copyright:
© 2023 European Association for the Study of the Liver
PY - 2023/7
Y1 - 2023/7
N2 - Intrahepatic cholangiocarcinoma (iCCA) develops inside the liver, between bile ductules and the second-order bile ducts. It is the second most frequent primary liver cancer after hepatocellular carcinoma, and its global incidence is increasing. It is associated with an alarming mortality rate owing to its silent presentation (often leading to late diagnosis), highly aggressive nature and resistance to treatment. Early diagnosis, molecular characterisation, accurate staging and personalised multidisciplinary treatments represent current challenges for researchers and physicians. Unfortunately, these challenges are beset by the high heterogeneity of iCCA at the clinical, genomic, epigenetic and molecular levels, very often precluding successful management. Nonetheless, in the last few years, progress has been made in molecular characterisation, surgical management, and targeted therapy. Recent advances together with the awareness that iCCA represents a distinct entity amongst the CCA family, led the ILCA and EASL governing boards to commission international experts to draft dedicated evidence-based guidelines for physicians involved in the diagnostic, prognostic, and therapeutic management of iCCA.
AB - Intrahepatic cholangiocarcinoma (iCCA) develops inside the liver, between bile ductules and the second-order bile ducts. It is the second most frequent primary liver cancer after hepatocellular carcinoma, and its global incidence is increasing. It is associated with an alarming mortality rate owing to its silent presentation (often leading to late diagnosis), highly aggressive nature and resistance to treatment. Early diagnosis, molecular characterisation, accurate staging and personalised multidisciplinary treatments represent current challenges for researchers and physicians. Unfortunately, these challenges are beset by the high heterogeneity of iCCA at the clinical, genomic, epigenetic and molecular levels, very often precluding successful management. Nonetheless, in the last few years, progress has been made in molecular characterisation, surgical management, and targeted therapy. Recent advances together with the awareness that iCCA represents a distinct entity amongst the CCA family, led the ILCA and EASL governing boards to commission international experts to draft dedicated evidence-based guidelines for physicians involved in the diagnostic, prognostic, and therapeutic management of iCCA.
KW - diagnosis
KW - intrahepatic cholangiocarcinoma
KW - management
KW - risk factors
KW - staging
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85163913837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163913837&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2023.03.010
DO - 10.1016/j.jhep.2023.03.010
M3 - Article
C2 - 37084797
AN - SCOPUS:85163913837
SN - 0168-8278
VL - 79
SP - 181
EP - 208
JO - Journal of hepatology
JF - Journal of hepatology
IS - 1
ER -